Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
03 juin 2014 13h06 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...